Kodiak Sciences Jumps 17% After-Hours on Phase 3 Readout Set for Monday
KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.2× avg).
Summary
Kodiak Sciences surged 17% to $38 in after-hours trading after announcing it will report topline Phase 3 results for two wet AMD treatments, Zenkuda and KSI-501, at 8:30 a.m. ET on Monday. The readout is a binary event for the company, which reported a $65.6 million net loss and $125.9 million in cash in Q2 2026, with a going concern warning. Positive data could validate the pipeline and extend the runway; negative data would likely trigger a sharp selloff. The stock closed down 2.6% at $32.35 on Friday before the after-hours move.
At the time of this announcement, KOD was trading at $38.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.94 to $47.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.